Trial Profile
A Phase II Trial of Alemtuzumab (Campath-1H) and Rituximab (Rituxan) in Patients With Previously Untreated CLL.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 01 May 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
- 01 May 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.
- 10 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.